or Try an Advanced Search...

    Technical Analysis for GTG - Genetic Technologies Limited

    Grade Last Price % Change Price Change
    C 0.115 -8.00% -0.010
    GTG closed down 8.0 percent on Wednesday, April 24, 2024, on 2 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Apr 29
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical GTG trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Bullish Engulfing Bullish -8.00%
    Calm After Storm Range Contraction -8.00%
    Stochastic Reached Oversold Weakness -8.00%
    Wide Bands Range Expansion -8.00%
    Older End-of-Day Signals for GTG ...

       Recent Intraday Alerts

    Alert Time
    Gapped Down (Full) about 12 hours ago
    Down 5% about 12 hours ago
    Down 3% about 12 hours ago
    Down 2% about 12 hours ago
    Down 1% about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    GTG Chart by TradingView
    Basic chart:

    Profile

    Genetic Technologies Limited Description

    Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Health Medicine Healthcare Biotechnology Cancer Imaging Clinical Medicine Breast Cancer Medical Tests Healthcare Professionals Molecular Diagnostics Medical Genetics

    Is GTG a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
    Apr 18 Genetic Technologies Announces $2 Million Registered Direct Offering
    Apr 17 New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
    Apr 16 GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
    Apr 12 Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Apr 11 GTG to pilot GeneType in Breast Screen centers across the U.S.
    Apr 8 EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
    Apr 2 Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market
    Mar 26 GTG Global Collaborations and Innovation Update
    Mar 25 GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
    See more GTG news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.2
    52 Week Low 0.002
    Average Volume 84,280
    200-Day Moving Average 0.057
    50-Day Moving Average 0.133
    20-Day Moving Average 0.147
    10-Day Moving Average 0.151
    Average True Range 0.014
    RSI (14) 39.76
    ADX 25.48
    +DI 25.471
    -DI 30.030
    Chandelier Exit (Long, 3 ATRs) 0.142
    Chandelier Exit (Short, 3 ATRs) 0.158
    Upper Bollinger Bands 0.184
    Lower Bollinger Band 0.109
    Percent B (%b) 0.08
    BandWidth 50.922
    MACD Line 0.000
    MACD Signal Line 0.006
    MACD Histogram -0.0056
    Fundamentals Value
    Market Cap 950.1 Million
    Num Shares 8.26 Billion
    EPS 0.00
    Price-to-Earnings (P/E) Ratio -57.50
    Price-to-Sales 2948.61
    Price-to-Book 4.44
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.115
    Resistance 3 (R3) 0.115 0.115 0.115
    Resistance 2 (R2) 0.115 0.115 0.115 0.115
    Resistance 1 (R1) 0.115 0.115 0.115 0.115 0.115
    Pivot Point 0.115 0.115 0.115 0.115 0.115
    Support 1 (S1) 0.115 0.115 0.115 0.115 0.115
    Support 2 (S2) 0.115 0.115 0.115 0.115
    Support 3 (S3) 0.115 0.115 0.115
    Support 4 (S4) 0.115